Onc.AI
AI NativeNon-invasive radiomic-based biomarkers for clinical decision support
Est 2020|Raised $31M
Non-invasive radiomic-based biomarkers for clinical decision support
Published Jul 14, 2026
| Starting Price | Not publicly listed | Typically custom/enterprise (vendor pricing not publicly posted) | Often contract-based; pricing varies by deployment and algorithm (vendor materials indicate contract models) |
| Primary Focus | CT-based radiomics biomarkers and prognostic/predictive models in oncology (notably NSCLC) for pharma trials and investigational clinical decision support | Multimodal precision medicine platform (molecular, clinical data; trial matching; provider and life-science partnerships) | Radiology AI deployment and workflow automation across multiple radiology indications; less focused on oncology-specific predictive biomarkers |
| Key Strength | Specialization in CT radiomics and trial-focused biomarker use cases; active in pharma collaborations and prospective validation efforts | Large data network and multimodal capabilities; established provider relationships | Platform focus on imaging workflow integration and a broad set of radiology applications |
| Key Weakness | Limited public independent user reviews; pricing and regulatory status not fully public; investigational status for clinical use | Not imaging-biomarker specific for oncology; platform complexity and cost can vary | May not provide oncology-specific predictive endpoints required for drug development or treatment selection |
—